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Polyclonal anti-TAU antisera directed against native Tau protein and the NH,-terminal side of the mouse TAU sequence were used to determine 
the nature of the TAU variants present in Alzheimer brains and in PHFs. These antibodies labelled specifically neurofibrillary tangles and plaque 
neurites in Alzheimer brains. On immunoblots of PHF extracts, two entities of 69 and 130 kDa were identified. These TAU-related species were 
absent from control brains. Protein immunoblot of total Alzheimer and control supernatants were shown to contain the same 4-5 TAU variants 
but none of the 69 and 130 TAU-related entities found in PHFs. These data suggest that specific TAU species are present in PHFs. 
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1. INTRODUCTION 
The Alzheimer disease is characterized by two types 
of lesions: the neurofibrillary tangles (NFTs) and the 
senile plaques. Senile plaques are formed with 
distrophic neurites surrounding an ‘amyloid core’. 
NFTs are made of 10 nm paired helical filaments 
(PHFs) which are present both in the perikarya of af- 
fected neurons and in the distrophic neurites of the 
senile plaques (see [l] for a review). The finding that 
PHFs contain TAU epitopes [2] has received strong 
support during the past few years [3,4]. 
In the mature brain, TAU proteins consist of 4-5 
variants (50-70 kDa) [5] whereas at immature stages 
only 2-3 variants of 45-48 kDa are expressed [6]. The 
C-terminal end of all these variants is highly conserved 
and contains repeats which have been shown to be the 
tubulin binding sites [7-91; three and four repeats are 
present, respectively, in the immature and mature TAU 
variants. Two other microtubule-associated proteins 
known as MAP2 [lo] and MAP4 (C. Bulinski, personal 
communication) also contain repeated sequences in 
their C-terminal domain. These repeats are highly 
homologous to those found in TAU proteins. Several 
studies suggest that more than one TAU variant is pre- 
sent in PHFs [ 11,121 and that the entire molecule is in- 
corporated into NFTs [12,13]. However, the exact 
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nature of TAU isoforms found in PHFs remains 
unclear. To answer this question the first antibody 
(lE9) used in this work was raised against the whole 
TAU sequence. This antibody was therefore potentially 
able to detect not only TAU proteins but also MAP2, 
MAP4 and eventually other microtubule-associated 
proteins containing repeated sequences homologous to 
those present in TAU proteins. Another antibody 
(B19-1) was raised against a short sequence present in 
the N-terminal end of TAU protein which is absent in 
both MAP2 and MAP4. This N-terminal sequence is 
present in all mouse [7], rat [ 131, bovine [8,14] and 
human [12] TAU sequences established so far and is 
specific of TAU proteins. Using these two antibodies 
we show in this work that a major TAU variant of 
69 kDa is present in the PHFs together with an im- 
munologically larger TAU-related protein of 130 kDa. 
2. MATERIALS AND METHODS 
Brains from 5 Alzheimer (80-98 years old) and 5 control patients 
(61-88 years old) who had died of non-neurological diseases were ob- 
tained 7-24 h post-mortem, and were stored at -70°C. The clinical 
diagnosis was confirmed histologically by the presence of plaques and 
tangles in temporal cortex and hippocampus. 
Total and heat-treated supernatants were prepared as previously 
described [6]. 
A polyclonal antiserum (B19-1) was raised in rabbits against an 
oligopeptide corresponding to amino acids 29-48 of the mouse TAU 
sequence [7]. The respective peptide was generated by solid phase 
synthesis (Multiple Peptide Systems, San Diego, CA) and covalently 
linked to keyhole limpet hemocyanine (KLH) (Pierce, Rockford, IL) 
[12]. Male rabbits were immunized with 25Opg antigen in the 
presence of a synthetic glycolipid, BAY R-1005 (Bayer AG, 
Leverkusen) as adjuvant (1 mg/kg). Booster injections were given 
every three weeks. After 18 weeks the rabbits were sacrificed and the 
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serum collected. A polyclonal antibody (lE9) directed against native 
rat brain TAU was raised as previously described [6] and purified by 
affinity chromatography. 
Antisera (l&X@ for Bl9-1 and lf200 for lE9) were applied on sec- 
tions of paraffin-emb~ded, formalin-fixed Alzheimer hippocampus. 
Sections were successively incubated with a biotinylated anti-rabbit 
antibody and with horseradish peroxidase-streptavidin (Amersham) 
and the peroxidase was localized with diaminobenzidine [IS]. 
Hippocampi (7 g) were homogenized in 5 vols of buffer A (0.1 M 
Mes, 0.5 mM MgClz, 1 mM EGTA, 0.1 mM EDTA, 1 mM GTP, 
0.4 mM PMSF, 5 pM leupeptine, 10 mM ben~idine, 1 mM mer- 
captoethanol, 0.25 mglml trypsin inhibitor, pH 6.4) plus 0.34 M 
sucrose and filtered through a 100pm muslin screen. The sucrose 
concentration of the filtrate was brought to 1 M and 7 ml of the mix- 
ture were layered over a discontinuous ucrose gradient of 1.2 M and 
1.8 M (9 ml each). After centrifugation at 5000 x g for 1 h at 4°C. 
the l/l.2 M interface was diluted to 0,s M with buffer A and 
material was pelleted at 110000 x g for 45 min at 4°C. The pellet was 
suspended in 0.34 M sucrose, iayered over an equal volume of 1 M 
sucrose and centrifuged at 190000 x g for 90 min at 4°C. The pellet 
was resuspended in one volume of 0.34 M sucrose, layered over a gra- 
dient of 1.2 M and 1.8 M sucrose (9 ml each) and centrifuged at 
190000 x g for 2 h. The 1.2/1.8 M interface was pelleted as above. 
The pellet was diluted in 1 ml of buffer A, incubated with 100 ~1 of 
2% SDS for 5 min at 20°C and centrifuged at 11000 x g for 10 min 
to collect the PI-IFS. Such mild SDS treatment allows one to obtain 
apparently non-contaminated PHF preparations and, subsequently, 
much clearer protein immunoblots. 
PHF fractions were absorbed onto carbon-coated grids and stained 
with 1% phosphotungstic acid (pH 7.4). 
Heat-treated supernatants and sonicated PHFs were boiled for 
5 min in 2.3% SDS, 10% glycerol and 5% mer~pto~hanol and sub- 
jected to SDS-PAGE (10% and 12%, respectively). Transfer to the 
nitroceliulose and treatment with antibodies (dilutions: 115000 for 
BlP-1, l/200 for lE9) were performed as previously described [6]. 
3. RESULTS 
The polyclonal antiserum B19-1 used in this study is 
directed against the NHz-terminal side of the mouse 
TAU sequence described by Lee et al. [7] whereas 
polyclonal lE9 was raised against the entire TAU 
molecule. On Western blot, B19-1 (Fig. 1A and 3A) 
and lE9 (not shown) reacted with the juvenile (48 kDa) 
and adult (50-70 kDa) TAU variants present in total 
and heat-stable supernatants from 6 days and adult rat 
brains as well as with the adult human brain variants. 
Staining of tangles by the B19-1 (Fig. 1B) and lE9 (not 
shown) was tested on hippocampus tissue sections of 
patients with Alzheimer disease. Both antisera strongly 
Iabelled NFTs and numerous neurites surrounding 
senile plaque cores. 
PHFs were purified from the hippocampus region 
which is rich in NFTs from 5 Alzheimer brains. The 
same procedure of purification was applied to 4 non- 
Alzheimer brains as control. The three successive 
sucrose gradients greatly enriched the pool of PHFs. 
The interface 1.2j1.8 of the last gradient contained 
cellular components contaminating PHFs. Mild treat- 
ment of this fraction with SDS for S min at room 
temperature solubilized most cellular fragments giving 
a fraction highly enriched in NFTs of different size. 
These NFTs retained their characteristic Congo red 
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Fig. 1. (A) Immunoblot with anti TAU 819-l of 6 days (1, 2) and 
adult (3, 4) rat brain extracts. (1, 3) Total 10’ g supernatants; (2, 4) 
heat-treated supernatants. (B) Immunocytochemical staining of 
NFTs and senile plaques in hipp~~pal sections of Alzheimer 
disease patient. Bar = 20pm. 
birefringence (Fig. 2A). At a higher magnification, the 
tangles have elongated forms with filaments visible in- 
side (Fig. 2B). At the electron microscopic level, NFTs 
were constituted of bundles of 23-nm paired helical 
filaments with a half-periodicity of 85-100 nm 
(Fig. 2C, D). 
B19-1 was used to compare the soluble TAU variants 
present in Alzheimer and control brain extracts 
(Fig. 3A). Western blot analysis of heat-stable super- 
natants from hipp~~pus regions revealed that the 
distribution of the TAU-related proteins was similar in 
Fig. 2. Congo red staining (A, B) and electron microscopy (C, D) of 
PHFs. Bars = A: 100 hum; 8: 20 pm; C and D: 100 nm. 
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Fig. 3. Western blot analysis with the Bl9-1 antibody of the TAU variants present in Alzheimer and control brains (A) and in PHFs (B). (A) 
Heat-treated supernatants (20 ,ug) of Alzheimer (lanes l-3) and control (lanes 4-6) brains. (B) Alzheimer brain supernatant (1). Alzheimer (2) 
and control (5) homogenates. Pellet (3) and supematant (4) of PHF extracts. 
the Alzheimer and the control brain supernatants with 
several TAU variants (50-65 kDa) present in both 
cases. The same pattern was obtained with the 
polyclonal lE9 (not shown). None of these antibodies 
detected a TAU variant specific or present in higher 
quantity in Alzheimer brain supernatants. 
In contrast, analysis of SDS Iysates of total 
homogenates prepared from Alzheimer hippocampi 
showed the presence of a TAU-related entity of 69 kDa 
which was the dominant TAU species (Fig. 3B). The 
same 69 kDa species was detected in the SDS extracts 
of the purified PHFs fraction. Two other entities of 
about 68 and 70 kDa were also feintly detected. These 
bands were absent in total soluble extracts (lane 1) and 
in fractions obtained from control brains (not shown). 
Another component of 130 kDa, present in variable 
quantity in homogenates (lane 2) of the different 
Alzheimer brains, was also detected in the PHF extracts 
(lane 3). This component was absent from control brain 
homogenates (lane 5). 
4. DISCUSSION 
Our PHF preparations contain one major TAU 
variant of 69 kDa as well as a protein of 130 kDa im- 
munologically related to TAU. Both entities were 
detected by a polyclonal antiserum directed against an 
amino acid stretch present in the N-terminal domain of 
all the TAU variants sequenced so far [7,8,13,14]. 
The 69 kDa entity does not seem to be over- 
expressed in the brain of the demented patients since 
the immunoblots obtained with supernatants from con- 
trol and Alzheimer brains were identical. Flament et al. 
have recently reported that two TAU entities of 64 and 
69 kDa are present in Alzheimer brain homogenates 
f 161. The same authors have observed a decrease in the 
apparent molecular weight of these entities after 
phosphatase treatment. It is not clear whether the 
69 kDa species described by these authors is identical to 
the TAU variant extracted from our PHF preparations 
since phosphatase treatment of our extracts was not 
conclusive. 
Previous studies have reported that PHFs contain 
several adult TAU forms and at least one juvenile TAU 
variant [I 1,12,17}. Such entities were not seen in our 
preparations and this might depend either on the an- 
tibodies or on the purification procedure of the PHFs 
we used. 
Two arguments are against the first assumption: (i) 
the B19 anti-TAU was raised against a TAU domain 
which is present in all adult and juvenile TAU forms se- 
quenced so far; (ii) this antibody detected all the adult 
and juvenile TAU entities when tested with rat and 
human brain supernatants (Fig. 1A and 3A). We may 
therefore conclude that only the 69 and 130 kDa TAU 
entities are present in our PHF preparations. It has 
been shown recently [14] that the different TAU 
variants are produced by alternative splicing of a 
primary transcript generated from a single TAU gene 
which contains 13 exons. The variant transcripts cor- 
responded to mRNA species missing one or more exons 
[ 141. Four major TAU protein isoforms were identified 
by comparison with translation products of cDNA con- 
structs 1141. This suggests that the TAU variants ex- 
tracted from PHFs contain the sequence present in 
N-terminal region of the TAU gene since they were 
recognized by Bl9 anti-TAU. The presence of only two 
TAU variants in the PHF extracts might be explained 
by assuming that the other TAU species are released by 
the mild SDS treatment performed during the last step 
of our purification procedure. However, analysis of the 
supernatant obtained after this SDS mild exposure 
showed that, if TAU proteins were slightly released by 
this treatment, the 69 kDa component was always the 
predominant TAU entity (Fig. 3, lane 4). Finally, we 
come to the conclusion that the 69 kDa variant is an ab- 
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normal TAU entity or a TAU variant preferentially 
able to self-assemble in PHFs. 
The second entity clearly identified in PHF extracts 
is a protein of 130 kDa. This protein seems to be 
specific to the Alzheimer brain: (i) it was constantly 
found in all Alzheimer samples (homogenates and PHF 
extracts) tested and never in the controls; (ii) it was ab- 
sent or present in very low quantitities in total brain 
supernatants; (iii) it increased in concentration during 
the successive steps of PHF purification. Nukina et al. 
have also found high molecular weight entities 
(160- 180 kDa) in Alzheimer brain [ 181. They suggested 
that these entities are TAU aggregates. A TAU-related 
entity with unusual HMW seems to be present in some 
regions of normal brains; for instance Kosik et al. have 
found a 110 kDa entity immunologically related to 
TAU in the optic nerve [17]. A TAU variant of 
120 kDa which is under NGF control is also present in 
the PC12 pheochromocytoma cells [ 191. It is not clear 
whether our 130 kDa TAU-related protein is identical 
to one of these HMW entities. However, one might 
consider the possibility that PHFs are enriched in such 
a TAU variant because they are preferentially formed 
in a subset of neurons undergoing degeneration. This 
assumption is consistent with the observation that pro- 
minent abnormalities are spread along the olfactory 
bulb, hippocampal formation, entorhinal area and the 
associated cortices [20,21]. Another possibility, which 
does not contradict the first, would be that both the 
130 kDa and the 69 kDa entities are abnormal TAU 
variants which are able to self assemble to produce 
PHFs. 
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